Member Info for ontarget

Yes decent upside if anything positive happens with the FDA/phase 3 trial. Main downside risk for me is potential for a discounted fund-raise.

This one looks like he has a few bob as well:
https://companycheck.co.uk/director/903305962/MR-JAMES-ROBERT-KIGHT/summary

E.g. https://uk.linkedin.com/in/james-kight-1648435

Depends if 'Kight' is a typo in the RNS or not - there is at least one person called James Robert Kight that comes up on google.

Well someone called James Robert Kight was certainly buying on Friday - to the tune of 10M shares.

Strange now RNS at all yet on the AGM result. Did a riot break out at Evgen HQ??

That said, it's a bit of a no-brainer at this price with the significant cash underpinning as you said, whether short or longer term.

Nice summary tones, and agree re: short-term trading on AIM stocks. If I was of a shorter-term disposition I'd be more likely to look at commodities or forex, and definitely not tiny stocks like this which can be illiquid.

Are you suggesting you actually hold this stock radar?
Don't tell me, you got in at 30p years ago?

Agree the BOD should really be buying at this ridiculous price - they can’t all be skint surely?

website broken again?

Yes and we have the Juvenescence licensing deal as well, with $10.5m milestone payments due before expected product launch in H1 2023, whereupon EVG will receive royalties on sales, which could be very substantial indeed according to a recent interview with their CEO.

Yes huge potential and fully cashed-up to persue it.

News out, so hopefully nothing to prevent some director buying now - let’s see some of that today.

I hope it's not going to be a basic 'all resolutions passed' AGM RNS.
After Friday's result the company need to come out and promote themselves, talk about the exciting prospects to come. Some director buying would also work wonders.
What we don't need now is months of radio silence.

Just incredibly low volume I think.

Can't speak for anyone else, but I never read a post by MM as anything other than his own opinion (albeit posted sometimes annoyingly frequently). He never professed to have any specialist experience in the field or made definitive statements on where the SP was going, unlike a few on here.
Don't understand your obsession with an anonymous BB poster.

So strong buy/hold at this price for anyone with a bit of patience.

Yep. £11m cash (£11.6m as of 3 months ago), Juvenscence deal with $10m in milestone payments and royalties once product on sale (expected by early 2023), phase 2 positive result in breast cancer, glioma trial planned for early next year and potentially another breast cancer trial, undisclosed SHP related cancer indication as well.
All for £2m EV. Expected over-reaction to this morning's news and will likely gently rise towards 6p for a while with potential for out-of-the blue events e.g. licencing deals which the new CSO/CBO have been brought in to acquire.

Predictable small PI dumping at basically cash value, but it’s definitely not game over for this company. £11m+ cash in the bank, Juvenescence deal and oncology prospects are all still there.
Wonder if the recent II investors at 8p will be adding today?